X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Elsevier and FDA to work on AI algorithm for drug-induced liver injury

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Med-Tech Innovation Expo and Medilink UK renew partnership

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials

    Generic Version of Medrol

    Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Version of Medrol

    Fig extract for healthy blood sugar levels

    Fig extract for healthy blood sugar levels

    Novartis ligelizumab outperforms Roche’s Xolair in chronic urticaria clearance

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

    Amgen declares positive results for 2 Phase 3 BLINCYTO studies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Researchers target HER1 receptor for peptide cancer vaccine, therapeutic agents

Yuvraj_pawp by Yuvraj_pawp
25th July 2013
in Americas, News

Small proteins called peptides that consist of 10 to 50 amino acids are being studied as cancer vaccines and as possibly safer, more effective and less costly alternatives to the monoclonal-antibody-based drugs and small-molecule inhibitors now used to treat many malignancies.

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have identified two regions on the HER1/EGFR receptor, a protein important for cancer-cell growth and metastasis, and for poor patient survival, as targets for peptide agents.

The receptor molecules extend bristle-like from the surface of cancer cells in abnormally high numbers. It is activated by growth factors in the blood and released by other cells in the tumor, stimulating tumor growth.

“Our findings could lead to novel peptide vaccines and mimetic inhibitors that target HER1 in tumors of the breast, lung, colon and head and neck, and that overcome many of the significant shortcomings of antibody-based drugs such as cetuximab,” says principal investigator Pravin Kaumaya, PhD, director of the division of vaccine development at the OSUCCC – James.

“Such peptide agents might enable the development of combination immunotherapies using either HER2 vaccines or VEGF therapy that avoid the mechanisms of resistance or secondary treatment failures sometimes experienced with antibody treatment,” says Kaumaya, who is also professor of obstetrics and gynecology, of molecular and cellular biochemistry, and of microbiology at Ohio State.

The study is published in the Journal of Immunology.

HER1 is a member of the epithelial growth factor (EGF) family of cell-surface receptors, which includes the HER2 receptor. These receptors play a central role in the development of a variety of human cancers, including certain breast cancers, lung cancer, colorectal and head and neck cancers.

Kaumaya and his colleagues evaluated three sequences of peptides to determine which were the most specific and immunogenic (i.e., raised the strongest immune response in test animals), and therefore were best suited for use as vaccines or therapeutics. The three sequences, or epitopes, were based on the site of contact between HER1 and the growth factor that normally binds with it, epithelial growth factor (EGF).

Key technical findings included:

Two of the sequences (382–410 and 418–435) were identified as best for use as cancer therapy or a cancer vaccine;

The 382–410 epitope overlaps the binding site of cetuximab, an antibody agent that inhibits HER1 binding; however, the 418–435 epitope significantly inhibited tumor growth in transplantable breast and lung cancer models;

The vaccine constructs were highly immunogenic and established immunological memory in a rabbit model.

“Overall,” Kaumaya says, “our results show that the 418–435 epitope has great potential for use as a vaccine or treatment option for HER1-expressing cancers.”

Tags: America
Previous Post

Studies suggest new key to 'switching off' hypertension

Next Post

GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases

Related Posts

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Lilly to invest $400m to boost manufacturing capacity in US
Americas

Lilly to invest $400m to boost manufacturing capacity in US

26th November 2019
ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference
News

ConvergeHEALTH by Deloitte Launches New Digital Health Ecosystem Platforms at HLTH Conference

4th November 2019
Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment
Manufacturing

Foamix Enters Manufacturing Agreement with ASM Aerosol-Service for Topical Foam Treatment

4th November 2019
Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards
Manufacturing

Finalists revealed for CPhI Worldwides eagerly anticipated 2019 Awards

4th November 2019
Next Post

GSK adds to its commitment to GAVI Alliance to help protect millions more children against infectious diseases

Latest News

CPhI Worldwide pointing 2020 to be a strong year for pharma
Manufacturing

CPhI Worldwide pointing 2020 to be a strong year for pharma

3rd December 2019
Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases
Drug Development

Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

26th November 2019
Elsevier and FDA to work on AI algorithm for drug-induced liver injury
Americas

Elsevier and FDA to work on AI algorithm for drug-induced liver injury

26th November 2019
Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film
FDA Approvals

Aquestive Therapeutics Receives FDA Approval for Exservan Oral Film

26th November 2019
Med-Tech Innovation Expo and Medilink UK renew partnership
Drug Development

Med-Tech Innovation Expo and Medilink UK renew partnership

26th November 2019
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In